Luxembourg and the Netherlands this week joined the growing list of European countries to be included in the mutual recognition agreement between the EU and the FDA. Their inclusion followed the FDA's confirmation that their regulators have the capability to conduct inspections of biopharma manufacturing facilities at a level equivalent to that of the U.S.